Premium
Arsenic trioxide (As 2 O 3 ) inhibits murine WEHI‐3 leukemia in BALB/c mice in vivo
Author(s) -
Lai TungYuan,
Lin JenJyh,
Huang WenWen,
Kuo ShuChu,
Wen YenFang,
Lai ICheng,
Lin ChinChung,
Yang JaiSing,
Chung JingGung
Publication year - 2012
Publication title -
environmental toxicology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.813
H-Index - 77
eISSN - 1522-7278
pISSN - 1520-4081
DOI - 10.1002/tox.20650
Subject(s) - arsenic trioxide , acute promyelocytic leukemia , leukemia , in vivo , retinoic acid , apoptosis , chemistry , balb/c , spleen , cancer research , biology , microbiology and biotechnology , immunology , biochemistry , immune system , gene
Arsenic trioxide (As 2 O 3 ) is used clinically to treat acute promyelocytic leukemia (APL) and has activity in vitro for induction of apoptosis in several solid tumor cell lines. To investigate the potential therapeutic application of As 2 O 3 for leukemia, we analyzed the effects of As 2 O 3 on the WEHI‐3 cells‐induced orthotopic leukemia animal model in vivo in this study. We established the WEHI‐3 cells leukemia mice through the injection of murine WEHI‐3 cells into BALB/c mice, and they were then treated with As 2 O 3 (0.9 and 4.5 mg kg −1 ; p.o.) and/or combined with all‐trans‐retinoic acid (ATRA), (30 mg kg −1 ; i.p.). The results indicated that (1) As 2 O 3 alone or As 2 O 3 combined with ATRA promoted the total survival rate of leukemia mice and these effects are dose‐dependent; (2) As 2 O 3 did not affect the body weight but decreased the spleen weight; however, it did not affect liver weight; (3) As 2 O 3 alone or As 2 O 3 combined with ATRA increased the levels of CD3 and CD19, indicating that the differentiation of T and B cells were promoted; and (4) As 2 O 3 alone or As 2 O 3 combined with ATRA did not change the levels of Mac‐3 and CD11b markers, indicating that the differentiation of the precursor of macrophage were not inhibited. Based on these observations, As 2 O 3 alone or As 2 O 3 combined with ATRA have efficacious antileukemia activity in WEHI‐3 cells leukemia in vivo . © 2010 Wiley Periodicals, Inc. Environ Toxicol, 2012.